GC
AEGR

Globeflex Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Globeflex Capital’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-83
Closed – – 574
2016
Q1 		$0 Buy
83
+45
+118% +$279 ﹤0.01% 534
2015
Q4 		$0 Sell
38
-14,447
-100% -$174K ﹤0.01% 551
2015
Q3 		$197K Sell
14,485
-31,167
-68% -$555K 0.04% 381
2015
Q2 		$866K Sell
45,652
-131
-0.3% -$2.83K 0.16% 250
2015
Q1 		$1.2M Buy
45,783
+45,759
+190,663% +$1.16M 0.23% 175
2014
Q4 		$1K Sell
24
-5
-17% -$126 ﹤0.01% 506
2014
Q3 		$1K Buy
+29
New +$900 ﹤0.01% 531

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Globeflex Capital's AEGR Position: Q2 2016 in Review

Globeflex Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 83 shares.

Globeflex Capital first reported a position in AEGR in Q3 2014 and held it in 7 quarters. The position peaked at $1.2M in Q1 2015. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Globeflex Capital reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Globeflex Capital sold 83 Aegerion Pharmaceuticals shares in Q2 2016.
  • Globeflex Capital first reported a position in Aegerion Pharmaceuticals in Q3 2014 and held it in 7 quarters.
  • Globeflex Capital's Aegerion Pharmaceuticals position peaked at $1.2M in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Globeflex Capital's 13F filing for Q2 2016, filed 10 Aug 2016.